{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:38:42Z","timestamp":1793140722917,"version":"4.5.0"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"International Research Network","award":["IRN59W0005"],"award-info":[{"award-number":["IRN59W0005"]}]},{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["GRB-APS-13-58-30-10"],"award-info":[{"award-number":["GRB-APS-13-58-30-10"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jns.2018.02.010","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T02:30:52Z","timestamp":1517797852000},"page":"67-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"special_numbering":"C","title":["Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm"],"prefix":"10.1016","volume":"389","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-2064","authenticated-orcid":false,"given":"Roongroj","family":"Bhidayasiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onanong","family":"Jitkritsadakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2018.02.010_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.010_bb0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/01.wnl.0000342200.58823.6a","article-title":"Levels of evidence: taking neurology to the next level","volume":"72","author":"Gross","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.010_bb0015","series-title":"Summary of Evidence-based Guideline for Clinicians: Treatment of Tardive Syndromes","author":"American Academy of Neurology","year":"2013"},{"key":"10.1016\/j.jns.2018.02.010_bb0020","series-title":"Summary of Evidence-based Guideline for Patients and Their Families: Treating and Managing Tardive Syndromes","author":"American Academy of Neurology","year":"2013"},{"key":"10.1016\/j.jns.2018.02.010_bb0025","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/01.nrl.0000038585.58012.97","article-title":"Classification and treatment of tardive syndromes","volume":"9","author":"Fernandez","year":"2003","journal-title":"Neurologist"},{"key":"10.1016\/j.jns.2018.02.010_bb0030","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/pgmj.2010.103234","article-title":"Spectrum of tardive syndromes: clinical recognition and management","volume":"87","author":"Bhidayasiri","year":"2011","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jns.2018.02.010_bb0035","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1212\/WNL.32.12.1335","article-title":"Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs","volume":"32","author":"Burke","year":"1982","journal-title":"Neurology"},{"issue":"Pt 11","key":"10.1016\/j.jns.2018.02.010_bb0040","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/brain\/121.11.2053","article-title":"The natural history of tardive dystonia. A long-term follow-up study of 107 cases","volume":"121","author":"Kiriakakis","year":"1998","journal-title":"Brain"},{"key":"10.1016\/j.jns.2018.02.010_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.870040208","article-title":"Tardive akathisia: an analysis of clinical features and response to open therapeutic trials","volume":"4","author":"Burke","year":"1989","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.010_bb0050","series-title":"Clinical Practice Guideline Process Manual","author":"Gronseth","year":"2011"},{"key":"10.1016\/j.jns.2018.02.010_bb0055","series-title":"Amendments to the 2011 American Academy of Neurology Clinical Practice Guideline Process Manual","author":"Gronseth","year":"2015"},{"key":"10.1016\/j.jns.2018.02.010_bb0060","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.4088\/JCP.16m11049","article-title":"Effect of antipsychotic type and dose changes on tardive dyskinesia and parkinsonism severity in patients with a serious mental illness: The Curacao extrapyramidal syndromes study XII","volume":"78","author":"Mentzel","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0070","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0075","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/WNF.0000000000000061","article-title":"Tetrabenazine for tardive tremor in elderly adults: a prospective follow-up study","volume":"38","author":"Kertesz","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0080","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","article-title":"Dopamine depleters in the treatment of hyperkinetic movement disorders","volume":"17","author":"Jankovic","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jns.2018.02.010_bb0085","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jns.2018.02.010_bb0090","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2215-0366(17)30236-5","article-title":"Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"4","author":"Anderson","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0095","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1212\/WNL.0000000000003960","article-title":"Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study","volume":"88","author":"Fernandez","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.010_bb0100","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O'Brien","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.jns.2018.02.010_bb0105","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0110","first-page":"61","article-title":"Tolerability of Valbenazine (NBI-98854) in subjects with tardive dyskinesia and a diagnosis of schizophrenia or mood disorder","volume":"47","author":"Josiassen","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.jns.2018.02.010_bb0115","unstructured":"FDA approves first drug to treat tardive dyskinesia [online]. Available at: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm552418.htm."},{"key":"10.1016\/j.jns.2018.02.010_bb0120","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMp1704898","article-title":"Efficient trial design - FDA approval of valbenazine for tardive dyskinesia","volume":"376","author":"Davis","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.010_bb0125","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/WNF.0000000000000086","article-title":"Treatment of tardive dystonia induced by antipsychotics, old and new","volume":"38","author":"Gourzis","year":"2015","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0130","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ajp.2013.12.016","article-title":"Management of tardive syndromes with clozapine: a case series","volume":"8","author":"Grover","year":"2014","journal-title":"Asian J. Psychiatr."},{"key":"10.1016\/j.jns.2018.02.010_bb0135","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00415-011-6235-2","article-title":"Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study","volume":"259","author":"Kimiagar","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2018.02.010_bb0140","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2011.12.010","article-title":"Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial","volume":"315","author":"Iwata","year":"2012","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2018.02.010_bb0145","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1212\/WNL.0000000000002370","article-title":"Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia","volume":"86","author":"Pouclet-Courtemanche","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2018.02.010_bb0150","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.parkreldis.2017.05.010","article-title":"Long-term follow-up of bilateral subthalamic deep brain stimulation for refractory tardive dystonia","volume":"41","author":"Deng","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2018.02.010_bb0155","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.parkreldis.2014.11.013","article-title":"Temporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulation","volume":"21","author":"Shaikh","year":"2015","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.jns.2018.02.010_bb0160","doi-asserted-by":"crossref","first-page":"455","DOI":"10.12809\/hkmj134082","article-title":"Pallidal deep brain stimulation: an effective treatment in Chinese patients with tardive dystonia","volume":"20","author":"Woo","year":"2014","journal-title":"Hong Kong Med. J."},{"key":"10.1016\/j.jns.2018.02.010_bb0165","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.pjnns.2016.04.006","article-title":"Deep brain stimulation of the internal globus pallidus for disabling haloperidol-induced tardive dystonia. Report of two cases","volume":"50","author":"Sobstyl","year":"2016","journal-title":"Neurol. Neurochir. Pol."},{"key":"10.1016\/j.jns.2018.02.010_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S1092852916000730","article-title":"Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia","volume":"21","author":"Meyer","year":"2016","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jns.2018.02.010_bb0175","series-title":"Movement Disorders in Neurology and Neuropsychiatry","first-page":"81","article-title":"dyskinesia","author":"Withdrawal","year":"1992"},{"key":"10.1016\/j.jns.2018.02.010_bb0180","series-title":"Tardive Dyskinesia-A Task Force Report of the American Psychiatric Association","author":"American Psychiatric Task Force on Tardive Dyskinesia","year":"1992"},{"key":"10.1016\/j.jns.2018.02.010_bb0185","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","article-title":"Neuroleptic withdrawal in schizophrenic patients. A review of the literature","volume":"52","author":"Gilbert","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0190","unstructured":"Ingrezza prescribing information [online]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209241lbl.pdf."},{"key":"10.1016\/j.jns.2018.02.010_bb0195","unstructured":"Austedo prescribing information [online]. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208082s000lbl.pdf."},{"key":"10.1016\/j.jns.2018.02.010_bb0200","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.biopsych.2012.04.032","article-title":"Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba","volume":"72","author":"Zhang","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/NRL.0b013e3181f097b4","article-title":"Ginkgo biloba and cerebral bleeding: a case report and critical review","volume":"17","author":"Pedroso","year":"2011","journal-title":"Neurologist"},{"key":"10.1016\/j.jns.2018.02.010_bb0210","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0215","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.pnpbp.2004.05.016","article-title":"Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods","volume":"28","author":"Kinon","year":"2004","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0220","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","article-title":"Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study","volume":"64","author":"Bai","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0225","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.1097\/00004714-199502001-00007","article-title":"Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study","volume":"15","author":"Chouinard","year":"1995","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0230","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00004714-199704000-00004","article-title":"A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia","volume":"17","author":"Angus","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0235","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1056\/NEJM197110072851516","article-title":"Amantadine hydrochloride treatment of tardive dyskinesia","volume":"285","author":"Decker","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2018.02.010_bb0240","series-title":"Agressologie: revue internationale de physio-biologie et de pharmacologie appliquees aux effets de l'agression","first-page":"209","article-title":"Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs","volume":"9","author":"Crane","year":"1968"},{"key":"10.1016\/j.jns.2018.02.010_bb0245","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/WNF.0b013e3181ffde32","article-title":"Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"33","author":"Pappa","year":"2010","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0250","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1001\/archpsyc.1989.01810100050009","article-title":"Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy","volume":"46","author":"Lieberman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0255","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/ajp.147.4.445","article-title":"Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy","volume":"147","author":"Thaker","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0260","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-199202000-00007","article-title":"Is diltiazem effective in treating the symptoms of (tardive) dyskinesia in chronic psychiatric inpatients? A negative, double-blind, placebo-controlled trial","volume":"12","author":"Loonen","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0265","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0140-6736(88)91110-5","article-title":"Diltiazem for tardive dyskinesia","volume":"1","author":"Leys","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2018.02.010_bb0270","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2006.03.023","article-title":"The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial","volume":"84","author":"Emsley","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.jns.2018.02.010_bb0275","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4088\/JCP.v68n0309","article-title":"Treatment of tardive dyskinesia with galantamine: a randomized controlled crossover trial","volume":"68","author":"Caroff","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0280","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4088\/JCP.09m05125yel","article-title":"Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"72","author":"Zhang","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0285","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0290","first-page":"19","article-title":"Clinical observations of the treatment of tardive dyskinesia with haloperidol","volume":"75","author":"Frangos","year":"1975","journal-title":"Acta Psychiatr. Belg."},{"key":"10.1016\/j.jns.2018.02.010_bb0295","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00427742","article-title":"Tardive dyskinesia during and following treatment with haloperidol, haloperidol\u202f+\u202fbiperiden, thioridazine, and clozapine","volume":"59","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jns.2018.02.010_bb0300","first-page":"4","article-title":"Molindone and haloperidol in tardive dyskinesia","volume":"46","author":"Glazer","year":"1985","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0305","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1176\/appi.ajp.158.9.1511","article-title":"Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study","volume":"158","author":"Lerner","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0310","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.4088\/JCP.v68n1103","article-title":"Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study","volume":"68","author":"Lerner","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0315","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archpsyc.56.9.836","article-title":"Vitamin E treatment for tardive dyskinesia. Veterans affairs cooperative study #394 study group","volume":"56","author":"Adler","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0320","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1176\/ajp.150.9.1405","article-title":"Vitamin E treatment of tardive dyskinesia","volume":"150","author":"Adler","year":"1993","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0325","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1176\/ajp.149.6.773","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"149","author":"Egan","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0330","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.147.4.505","article-title":"Vitamin E in the treatment of tardive dyskinesia","volume":"147","author":"Elkashef","year":"1990","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0335","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00005053-199402000-00009","article-title":"Vitamin E in the treatment of tardive dyskinesia: a replication study","volume":"182","author":"Lam","year":"1994","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.jns.2018.02.010_bb0340","first-page":"167","article-title":"A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia","volume":"57","author":"Lohr","year":"1996","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0345","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00004850-199300830-00003","article-title":"Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment","volume":"8","author":"Peet","year":"1993","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jns.2018.02.010_bb0350","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0924933800002625","article-title":"Treatment of tardive dyskinesia with vitamin E","volume":"6","author":"Schmidt","year":"1991","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0355","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/ajp.149.3.391","article-title":"Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study","volume":"149","author":"Shriqui","year":"1992","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jns.2018.02.010_bb0360","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/00005053-199206000-00012","article-title":"alpha-Tocopherol treatment for tardive dyskinesia","volume":"180","author":"Spivak","year":"1992","journal-title":"J. Nerv. Ment. Dis."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X18300686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T12:28:21Z","timestamp":1751286501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X18300686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":72,"alternative-id":["S0022510X18300686"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.010","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2018.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}